![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Spadel SA | EU:SPA | Euronext | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-3.00 | -1.51% | 196.00 | 190.00 | 202.00 | 196.00 | 196.00 | 196.00 | 9 | 16:40:00 |
Death of non-executive director of SR Pharma plc London, 23 July 2003 - SR Pharma plc regretfully announces the death of Professor Tim Chard who was a non-executive director of the company. Chairman Eric Boyle said: "It is with deep sadness that we announce the death of Tim Chard on Sunday 20th July. Our thoughts and sincere condolences go out to his family and friends at this time. Tim became a director of the company in February 1997 and since then demonstrated a real commitment to the development of the business. His presence will be greatly missed by us all." About SR Pharma SR Pharma plc (www.srpharma.com) was founded in 1992 and develops novel medicines based on an improved understanding of the role played by the immune system in combating disease. The company's proprietary M. vaccae-based technology is the source of a number of product developments. SR Pharma is currently evaluating SRP299 and AVAC(TM) for the treatment of asthma and atopic dermatitis. The company is also investigating SRL172 as a vaccine adjuvant in cancer and infectious diseases. These products enhance the immune responses needed to combat cancer and infection, while regulating those that mediate allergies. For further information please contact: Steeve Lamontagne, SR Pharma plc Tel: +44 (0) 20 7307 1628 Email: s.lamontagne@srpharma.com END
1 Year Spadel Chart |
1 Month Spadel Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions